Previous in vitro studies demonstrated that AML cells are very sensitive to BCL2 inhibition.46 Notably, AKT signaling is closely interconnected with members of the BCL2 family47 and a combination of AKT- and BCL2-inhibitors in AML treatment could represent a beneficial combination.48 Therefore, components that regulate these pathways represent potential therapeutic targets. The gene discussed is BCL2; the disease is acute myeloid leukemia.